InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.95
(
-0.13%
)
US TECH 100
19,296.38
(
-0.20%
)
Dow Jones
42,101.86
(
0.18%
)
Brent Oil
74.25
(
-0.10%
)
Bitcoin
62,875.35
(
-0.12%
)
Post# of 253167
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120474
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238131

Thursday, 12/30/2021 7:09:00 PM

Thursday, December 30, 2021 7:09:00 PM

Post# of 253167
XERS +28%/AH on FDA approval of Recorlev for Cushing’s syndrome:

https://finance.yahoo.com/news/xeris-biopharma-announces-u-fda-213000491.html

Xeris Biopharma Holdings…today announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up